Skip to content
Medical Health Aged Care

“Retailers who sell deadly products should pay a price”: Research prompts calls to introduce tobacco retailer licensing fees in NSW

Public Health Association of Australia (NSW) and Australian and New Zealand Journal of Public Health 3 mins read

 

New research has prompted public health experts to call on the NSW Government to introduce tighter tobacco retail regulation and annual tobacco retailer licence fees to help continue to drive down smoking rates. 

 

Across the country there are a mishmash of licensing laws applied to retailers wishing to sell tobacco, also with varying fees. In NSW, there is no positive licensing scheme in place with retailers only having to notify Government once if they intend to sell tobacco, with no fees attached. 

 

A new article published in the Australian and New Zealand Journal of Public Health looks at the impact of significant changes to tobacco licensing introduced in SA in January 2007, when the annual cost of retail tobacco licences rose 15-fold from $12.90 to $200. It builds on prior research that showed that the initial fee increase led to an almost 24 percent decrease in the number of tobacco retailers within two years. 

 

Co-author Professor Caroline Miller, Director of Health Policy at the South Australia Medical Health Research Institute (SAHMRI), says the latest analysis of what happened in SA between 2009 and 2020 shows large fees are needed to prompt retailers to re-evaluate their selling of tobacco. 

 

“Since 2007, the fee in SA has only gradually been increased in line with indexation,” Prof Miller says.

 

“In the latest analysis, we found that the number of licences has continued to fall from 2,707 in 2009 to 1,810 in 2020, a 33 percent decline over 11 years. However, this is only an incremental change. The research suggests significant fee introductions or hikes help prompt retailers to reevaluate being in the unethical business of tobacco.” 

 

Ms Anita Dessaix, Public Health Association of Australia (PHAA) NSW Spokesperson and Director, Cancer Prevention and Advocacy at Cancer Council NSW says it’s extremely disappointing and concerning that NSW lags behind most other states that have a higher standard of tobacco licensing.

 

“It’s ridiculous that in NSW retailers only have to notify Government if they are intending to sell tobacco, a product that if used as intended kills, while nearly all other states have licensing schemes with yearly fees attached. 

 

“Tobacco is still the leading preventable cause of death and disability in NSW, and the social costs of smoking have been estimated at about $8.4billion. In NSW around 6,700 deaths and more than 62,900 hopsitalisations were attributed to smoking. NSW retailers who sell these deadly products get off scot-free, without paying a licensing fee, while people who smoke pay the ultimate price with their health or life.  

 

“Tobacco is sold in most supermarkets, in corner stores, petrol stations and tobacconists across the state – undermining NSW residents genuine attempts to quit. A positive licensing scheme could instead help fund compliance and enforcement efforts, as well as broader efforts to encourage and support people to quit. 

 

“While current smoking among across the NSW adult population has steadily declined over the past 20 years and is now sitting at 11.4%, among the most disadvantaged quintile current smoking is significantly higher at 19.4%. 

 

“To help drive down smoking rates in NSW the Government needs to ask themselves – are we doing all we can? It’s time to put tobacco retailer licensing on the radar.” 

 

The Public Health Association of Australia is calling on all Governments to adopt a higher standard of licensing laws, including higher licensing fees, across the country to help drive down smoking rates. 

The Federal Government has committed to a target of decreasing smoking rates to below 10% by 2025, and to 5% or less by 2030.The National Tobacco Strategy has a number of actions relating to licensing, including considering restricting or prohibiting the sale of tobacco products in premises where alcohol is consumed, including vending machines; banning or restricting the sale of tobacco online and through smartphone applications; and considering a framework for a national licensing scheme, but these strategies are yet to be funded or implemented. 

ENDS

For media interviews please contact: 

Hollie Harwood, Strategic Communications Advisor, Public Health Association of Australia, [email protected], 0400 762 010 

Paris Lord, Media and Communications Manager, Public Health Association of Australia, [email protected] 0478 587 917

Note to editors: 

“Is it time to increase the cost of tobacco licences after 10 years of stagnation?” has been published here

Please credit the Australian and New Zealand Journal of Public Health.

 

All articles are open access and can be found here: https://www.journals.elsevier.com/australian-and-new-zealand-journal-of-public-health

 

The Australian and New Zealand Journal of Public Health is a publication of the Public Health Association of Australia.

 

 

 

 

More from this category

  • Medical Health Aged Care
  • 04/03/2026
  • 10:56
Roots

Roots Corporation Announces Strategic Review

TORONTO–BUSINESS WIRE– Roots Corporation (“Roots,” or the “Company”) (TSX: ROOT) announced that its Board of Directors (the “Board”) has initiated a review of strategic…

  • Contains:
  • Medical Health Aged Care
  • 04/03/2026
  • 08:56
Monash University

Monash University and Seaport Therapeutics Awarded up to $21 Million AUD from ARPA-H to Advance GlyphCeleTM, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function

ARPA-H award supports the development of an oral prodrug, based on the Glyph™ platform initially developed at the Monash Institute of Pharmaceutical Sciences (MIPS), to address dysfunctional gut lymphatics linked to metabolic disease and pancreatic cancer. Monash University has announced the award of support from the Advanced Research Projects Agency for Health (ARPA-H) to advance an oral prodrug of celecoxib – using the GlyphTM platform and designed to deliver therapy directly to the gut lymphatics – aiming to improve lymphatic function and advance the treatment of metabolic disease and pancreatic cancer by directly addressing local inflammation and lymphatic dysfunction. The…

  • Medical Health Aged Care, Women
  • 04/03/2026
  • 06:00
Australia New Zealand Gynaecological Oncology Group (ANZGOG)

STRIVE clinical trial now available in Aotearoa New Zealand to improve outcomes in vulvar cancer

MEDIA RELEASE: Wednesday,4March2025 The Australian New Zealand Gynaecological Oncology Group (ANZGOG) in partnership with the Canadian Cancer Trials Group (CCTG) announces the local opening of theSTRIVEclinical trial– Stratification of Vulvar Squamous Cell Carcinoma by HPV and p53 status to Guide Excisionclinical trial (CCTG Protocol VU.2; ANZGOG Protocol ANZGOG2109/2021). STRIVErepresentsan important stepforward in advancing evidence-based surgical management for women diagnosed with vulvar squamous cell carcinoma (VSCC). About the STRIVE Trial STRIVE is an international, prospective, stratification study designed to refine surgical decision-making for patients withprimary vulvar squamous cell carcinoma(VSCC) based ontumourbiology. The study is led globally by the CCTG and led…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.